NCT06607185 2026-04-22
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
Eli Lilly and Company
National Cancer Institute (NCI)
Astellas Pharma Inc
Parabilis Medicines, Inc.
Ruijin Hospital
Fudan University
I-Mab Biopharma US Limited
University Hospital, Akershus
Duke University